Yes; every MAH needs to nominate a local Pharmacovigilance Officer in South Africa.
"Responsibilities of the holder’s or applicant’s pharmacovigilance officer should include:
(i) the establishment and maintenance of a system which ensures that information about all suspected adverse reactions, which are reported to the holder or applicant, including to medical representatives and clinical research associates, is collected and collated so that it is accessible at a single point;
(ii) serving as a contact person for the Authority and NADEMC for all matters relating to pharmacovigilance;
(iii) the preparation of the following, either directly or by delegation/supervision, for submission to the authority: - ADR reports; - summary report for both serious and non-serious ADRs occurring in South Africa; - Periodic Safety Update Reports (PSURs) or Periodic Benefit-Risk Evaluation Reports (PBRER), when necessary; - company-sponsored post-registration study reports, when required; and - ongoing pharmacovigilance evaluation during the post-registration period; and
(iv) ensuring that any request from the Authority for additional information deemed necessary for the evaluation of the risk-benefit ratio of medicine, is provided to the Authoritypromptly and in accordance with all requirements,
(v) ensure that all the above responsibilities are met for all old and registered medicines on the Authority's Register that is marketed in South Africa. For products that are no longer marketed, post-marketing surveillance and reporting of ADRs should continue until six months after the expiry date of the last marketed batch."